PDCD1 and nasopharyngeal carcinoma: Currently, several phase III trials have shown that the addition of PD-1 inhibitors to gemcitabine-cisplatin as a first-line treatment significantly prolongs PFS in patients with recurrent or metastatic NPC (R/M NPC).